![Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/e7d31c91-9c6a-4ecc-87eb-2074454af216/gr1a.jpg)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
![Amazon.com: SK hynix Platinum P41 2TB PCIe NVMe Gen4 M.2 2280 Internal SSD l Up to 7,000MB/S l Compact M.2 SSD Form Factor SSD - Internal Solid State Drive with 176-Layer NAND Amazon.com: SK hynix Platinum P41 2TB PCIe NVMe Gen4 M.2 2280 Internal SSD l Up to 7,000MB/S l Compact M.2 SSD Form Factor SSD - Internal Solid State Drive with 176-Layer NAND](https://m.media-amazon.com/images/I/71RGTZJJuqL.jpg)
Amazon.com: SK hynix Platinum P41 2TB PCIe NVMe Gen4 M.2 2280 Internal SSD l Up to 7,000MB/S l Compact M.2 SSD Form Factor SSD - Internal Solid State Drive with 176-Layer NAND
![ASCO 2022: A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma. ASCO 2022: A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1655310308142162762062aa07e4daeaf.jpg)
ASCO 2022: A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
![Rishabh Pant breaks Dhoni's 15-year-old huge record in solid 93-run knock vs BAN | Cricket - Hindustan Times Rishabh Pant breaks Dhoni's 15-year-old huge record in solid 93-run knock vs BAN | Cricket - Hindustan Times](https://images.hindustantimes.com/img/2022/12/23/1600x900/Bangladesh-India-Cricket-30_1671785849910_1671785849910_1671786804388_1671786804388.jpg)
Rishabh Pant breaks Dhoni's 15-year-old huge record in solid 93-run knock vs BAN | Cricket - Hindustan Times
![India vs Bangladesh 2nd Test Day 3 Highlights: IND's top four blown away in 145-run chase, 45/4 at Stumps | Hindustan Times India vs Bangladesh 2nd Test Day 3 Highlights: IND's top four blown away in 145-run chase, 45/4 at Stumps | Hindustan Times](https://images.hindustantimes.com/img/2022/12/24/550x309/ANI-20221222185-0_1671847834505_1671847834505_1671847863737_1671847863737.jpg)
India vs Bangladesh 2nd Test Day 3 Highlights: IND's top four blown away in 145-run chase, 45/4 at Stumps | Hindustan Times
![High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - The Lancet Oncology High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/dbec891b-f83b-4e40-8287-f397533b9221/gr1.gif)
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - The Lancet Oncology
![Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial ... Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial ...](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-022-01667-1/MediaObjects/41375_2022_1667_Fig1_HTML.png)
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial ...
![Commonwealth Games 2022 Day 10 Highlights: Sharath-Sreeja win gold in TT mixed doubles; IND W bag silver in CWG final | Hindustan Times Commonwealth Games 2022 Day 10 Highlights: Sharath-Sreeja win gold in TT mixed doubles; IND W bag silver in CWG final | Hindustan Times](https://images.hindustantimes.com/img/2022/08/07/1600x900/Britain-Commonwealth-Games-Cricket-1_1659897855720_1659897855720_1659897889110_1659897889110.jpg)
Commonwealth Games 2022 Day 10 Highlights: Sharath-Sreeja win gold in TT mixed doubles; IND W bag silver in CWG final | Hindustan Times
![Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach | Scientific Reports Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-00989-x/MediaObjects/41598_2021_989_Fig1_HTML.png)
Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach | Scientific Reports
![SABCS 2022: DORA: A phase II, multicenter, international, non-comparator study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC) SABCS 2022: DORA: A phase II, multicenter, international, non-comparator study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC)](https://larvolclin.s3.us-west-2.amazonaws.com/16705636706640022416392c7564a0de.png)
SABCS 2022: DORA: A phase II, multicenter, international, non-comparator study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC)
![Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines | medRxiv Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/03/17/2021.03.17.21253131/F1.large.jpg)